VALNEVA revenue breakdown overview

VALNEVA revenue for the last year amounted to 169.60 M EUR, the most of which — 169.58 M EUR — came from its highest performing source at the moment, Development and Commercialization of Prophylactic Vaccines, the year earlier bringing 153.71 M EUR. The greatest contribution to the revenue figure was made by United States — last year it brought VALNEVA 48.59 M EUR, and the year before that — 32.96 M EUR.